Beam one-ups Wave as both show promise of genetic editing for AATD
Beam Therapeutics and Wave Life Sciences recently presented encouraging Phase 1/2 and Phase 1b/2a data, respectively, for their genetic editing therapies...
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Propanc Biopharma's CEO, James Nathanielsz, forecasts significant medical breakthroughs in pancreatic cancer treatment over the next decade, citing recent...
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
UCB's Bimzelx demonstrated superior efficacy over AbbVie's Skyrizi in a Phase 3 head-to-head study for psoriatic arthritis. At 16 weeks, 49.1% of patients on...
BioMarin drug acquired in buyout misses goal in rare disease study
BioMarin Pharmaceutical's experimental rare disease drug, BMN 401, acquired through a $270 million purchase of Inozyme, failed to meet one of its two...
Novo Nordisk to Unveil Semaglutide Data for Liver Disease Crisis
Novo Nordisk is presenting new data at the EASL Congress 2026, highlighting semaglutide's role in addressing Metabolic Dysfunction-associated Steatohepatitis...
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
Propanc Biopharma, Inc. has engaged a European Contract and Development Manufacturing Organization (CDMO) for the GMP production of its lead asset, PRP. This...
Clinical Trial Updates21 May 2026
Beam Therapeutics and Wave Life Sciences recently presented encouraging Phase 1/2 and Phase 1b/2a data, respectively, for their genetic editing therapies...
Clinical Trial Updates21 May 2026
Propanc Biopharma's CEO, James Nathanielsz, forecasts significant medical breakthroughs in pancreatic cancer treatment over the next decade, citing recent...
Clinical Trial Updates21 May 2026
UCB's Bimzelx demonstrated superior efficacy over AbbVie's Skyrizi in a Phase 3 head-to-head study for psoriatic arthritis. At 16 weeks, 49.1% of patients on...
Clinical Trial Updates21 May 2026
BioMarin Pharmaceutical's experimental rare disease drug, BMN 401, acquired through a $270 million purchase of Inozyme, failed to meet one of its two...
Clinical Trial Updates21 May 2026
Novo Nordisk is presenting new data at the EASL Congress 2026, highlighting semaglutide's role in addressing Metabolic Dysfunction-associated Steatohepatitis...
Clinical Trial Updates21 May 2026
Propanc Biopharma, Inc. has engaged a European Contract and Development Manufacturing Organization (CDMO) for the GMP production of its lead asset, PRP. This...
Regulatory Approvals22 May 2026
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., and Medincell announced that the European Medicines Agency (EMA)...
Regulatory Approvals22 May 2026
Cognition Therapeutics, Inc. held a productive meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026. The discussion focused on reviewing...
Regulatory Approvals21 May 2026
Revolution Medicines' RAS inhibitor demonstrated significant efficacy by doubling survival in a Phase 3 clinical trial for pancreatic cancer. This positive...
Regulatory Approvals21 May 2026
The FDA issued a warning letter to Chinese manufacturer Harbin Jixianglong Biotech for allegedly circumventing import restrictions on GLP-1 receptor agonist...
Regulatory Approvals21 May 2026
Roivant Sciences reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, alongside a comprehensive business update. Key...
Regulatory Approvals21 May 2026
BioSyent Inc. announced that Health Canada has approved Thyconvi™ (levothyroxine sodium), establishing it as the first and only levothyroxine oral solution...
Mergers and Acquisitions22 May 2026
Roche has signed a voluntary license agreement with the Medicines Patent Pool (MPP), a United Nations–backed public health body, to allow generic manufacturers...
Mergers and Acquisitions21 May 2026
Oorja Bio, a new biotechnology startup, has launched with $30 million in Series A funding from Westlake BioPartners. The Houston-based company announced plans...
Mergers and Acquisitions21 May 2026
Jupiter Neurosciences, Inc. has entered into a term sheet to acquire exclusive, perpetual United States licensing rights for ALA-002, a lead drug candidate...
Mergers and Acquisitions21 May 2026
Mentari Therapeutics, a spinout from Paragon Therapeutics, is set to go public through a reverse merger with InMed Pharmaceuticals. The deal, announced on...
Mergers and Acquisitions21 May 2026
Eton Pharmaceuticals has entered into a supply and distribution agreement with an affiliate of Knight Therapeutics, Inc. to acquire exclusive U.S....
Mergers and Acquisitions21 May 2026
Regeneron Pharmaceuticals has announced a significant partnership with Parabilis Medicines, committing up to $2.3 billion to create a new class of therapeutics...
Pharma competitive intelligence04 May 2026
Explains how pharma teams are shifting from quarterly reports to real-time signals for competitive intelligence, improving visibility and faster decision-making.
04 May 2026
Explains how clinical trial intelligence is reducing manual landscape analysis in drug development, improving speed, consistency, and planning decisions.
AI authoring platform04 May 2026
Explains how AI authoring platforms help create living, traceable regulatory submissions in life sciences, supporting consistency, updates, and compliance.
enterprise AI platform29 Apr 2026
An enterprise AI platform enables organizations to build, deploy, and manage AI solutions at scale. Learn how to evaluate trusted, explainable AI systems that meet compliance and transparency requirements in regulated industries.
KnolPersona31 Mar 2026
The EU Joint Clinical Assessment (JCA) regulation became mandatory for these product classes, creating a single EU-level clinical assessment that runs in parallel with the EMA regulatory review, not after it. For pharma teams accustomed to beginning HTA dossier preparation following regulatory approval, this is a strategic and operational discontinuity of the first order.
competitive intelligence29 Mar 2026
In the pharmaceutical industry, where a single competitor's Phase III readout can reshape a multi-billion dollar market overnight, the difference between knowing first and knowing last is not a matter of competitive preference. It is a matter of commercial survival.
Private by design. Speaks your language. Proven at scale
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
